Cargando…

The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials

OBJECTIVE: To ascertain the efficacy and safety of daunorubicin combined with cytarabine comparing with idarubicin combined with cytarabine as a standard induction therapy for acute Myeloid leukemia by a meta-analysis. METHODS: The randomized controlled trials included were retrieved from PubMed, Em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hanyu, Xiao, Xueting, Xiao, Qirong, Lu, Yanhong, Wu, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	4800
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302600/ https://www.ncbi.nlm.nih.gov/pubmed/32541448 http://dx.doi.org/10.1097/MD.0000000000020094

Ejemplares similares

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Busulfan and Fludarabine Conditioning Regimen Given at Hematological Nadir of Cytoreduction Fludarabine, Cytarabine, and Idarubicin Chemotherapy in Patients With Refractory Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation: A Single Arm Pilot Consort Study
por: Tang, Wei, et al.
Publicado: (2015)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis
por: Cao, Susu, et al.
Publicado: (2023)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China
por: Wang, Ling, et al.
Publicado: (2016)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China
por: Deng, Mengyue, et al.
Publicado: (2020)

The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts
por: Dragojew, Sylwia, et al.
Publicado: (2008)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy
por: Chen, Yi, et al.
Publicado: (2016)

The prognostic value of the peripheral blood cell counts changes during induction chemotherapy in Chinese patients with adult acute myeloid leukemia
por: Huang, Yuan-Mao, et al.
Publicado: (2021)

Idarubicin Plus Behenoyl Cytarabine and 6-thioguanine Compares Favorably with Idarubicin Plus Cytarabine-based Regimen for Children with Previously Untreated Acute Myeloid Leukemia: 10-Year Retrospective, Multicenter Study in Korea
por: Lee, Dae Hyoung, et al.
Publicado: (2010)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Pulmonary hypertension in patients with chronic myeloid leukemia
por: Song, Ik-Chan, et al.
Publicado: (2021)

Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis
por: Chen, Liang, et al.
Publicado: (2020)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Acute myeloid leukemia presenting as erythema nodosum: A case report
por: Xu, Xiaohan, et al.
Publicado: (2017)

DNMT3A mutations in Chinese childhood acute myeloid leukemia
por: Li, Weijing, et al.
Publicado: (2017)

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients
por: Ding, Ting, et al.
Publicado: (2019)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports
por: Wang, Hongxia, et al.
Publicado: (2020)

Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report
por: Pilalas, Dimitrios, et al.
Publicado: (2020)

Identification of the hub genes and pathways involved in acute myeloid leukemia using bioinformatics analysis
por: Tan, Youping, et al.
Publicado: (2020)

Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients
por: Qin, Ya-Zhen, et al.
Publicado: (2016)

Transformation from acute promyelocytic leukemia to acute myeloid leukemia with a CEBPA double mutation: A case report and review of the literature
por: Sun, Ye, et al.
Publicado: (2021)

The transformation of isolated gastric myeloid sarcoma into acute myeloid leukemia presenting with a complex karyotype and TLS-ERG gene fusion: A case report
por: Gao, Lu, et al.
Publicado: (2022)

Genetic polymorphisms of NAT2 and risk of acute myeloid leukemia: A case-control study
por: Zou, Yunding, et al.
Publicado: (2017)

Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report
por: Li, Xiang, et al.
Publicado: (2020)

Transformation from acute promyelocytic leukemia in pregnancy to acute myeloid leukemia with MLL-AF9 fusion gene: A case report and literature review
por: Gao, Yang, et al.
Publicado: (2023)

Clinical features and outcomes of hypocellular acute myeloid leukemia in adults: A Korean AML registry data
por: Song, Ik-Chan, et al.
Publicado: (2021)

Prognostic significance of long non coding maternally expressed gene 3 in pediatric acute myeloid leukemia
por: Xue, Hongjuan, et al.
Publicado: (2021)

Management of chronic myeloid leukemia presenting with isolated thrombocytosis and complex Philadelphia chromosome: A case report
por: Gao, Lu, et al.
Publicado: (2021)

Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study
por: Merdin, Alparslan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_41p3bv2ilkddsl5oehe9jt6khe